InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: turks post# 12556

Monday, 11/13/2017 7:54:03 PM

Monday, November 13, 2017 7:54:03 PM

Post# of 16885
Hey Turks,

Serenity was just pointing out that Zacks may be paid by Titan to cover Titan; and so if they are getting paid by Titan, there may be a bias in Titan's favor. So the comment is limited to Zacks' earning report.

I'm not too optimistic about the near-term future. Doctors are putting the ball in the insurance company's court; and the insurance companies are taking a lot of time to approve procedures. By the time the approval comes around, patients may no longer be interested.

Plus, insurance companies are not footing the whole bill for probuphine in many cases, and a lot of patients cannot afford it.

Braeburn seems to be blaming the REMS as well...requiring patients to be stablized on buprenorphine for six months, and requiring the implant to be held in a DEA approved facility, so that many doctors that want to buy it cannot keep it in their offices, thus they have to deal with the speciality pharmacy that fed ex's the implants to them on the actual day of the procedure...talk about a hassle.

Unless Braeburn lowers the price, I don't think things will get much better for probuphine anytime soon. They are being insanely greedy, and basically taking the position they would rather make no money at a high price than some money at a lower price. They also don't want to make probuphine more attractive than their injectables, because I believe them pay a higher royalty for probuphine. So they will wait to see what they can sell the injectables at, and then price probuphine just above that level. You and I know Indivior will beat them at injectables, but Derkacz got hired telling Apple Tree that he could beat Indivior. So his focus is going to be primarily there.

I was hoping for some congressional action, but that ain't gonna happen this year. Congress is focused entirely on the tax bill, so there will not be time for opioids this year. Next year though, especially before the mid-term elections, we will see some significant funding come through that hopefully will be directed to MAT, and hopefully having the DOJ going after insurance companies for failing to approve coverage. That type of thing will play well going into an election.

Derkacz is not a joke, but he inherited a mess from Sheldon, and he fired about a third of the sales reps. It will take time for that all to get sorted out.

The rest of the programs seem to be going well, we just need to find a way to pay for them! I'm hoping Titan sells 100% of its European rights to probuphine for about a year of operating expenses. Remember, the rods only cost $600, and so an EU company could sell them for $2,400 a year an still make a 100% profit.

Also, I think it makes sense for them to outlicense any but T3 if they can get cash upfront. T3 is the white whale.









Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News